RecruitingNot ApplicableNCT06968312

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

Testing Potential Enhancement of Standard Cognitive Processing Therapy for PTSD Using Hexadecanal: A Randomized Controlled Trial


Sponsor

Tel Aviv University

Enrollment

40 participants

Start Date

May 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Diagnosis of PTSD according to DSM-5
  • Age 18 years and over
  • Eligible for CPT treatment at the National Center for Traumatic Stress and Resilience

Exclusion Criteria4

  • Bipolar disorder, psychosis, neurological disorders
  • Drug Addiction
  • Parallel psychotherapy
  • Congenital or acquired anosmia.

Interventions

OTHERCognitive Processing Therapy + Hexadecanal

Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.

OTHERHexadecanal - Molecule Distribution in the Therapy room

Distribution of a naturally secreted molecule from body odor (Hexadecanal).


Locations(1)

Tel Aviv University

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06968312


Related Trials